Does danicamtiv improve LV systolic function and LA function in patients with HFrEF?
In a Phase 2a trial, the novel cardiac myosin activator danicamtiv was well tolerated and improved LV systolic function and LA function in patients with HFrEF.
AIMS: Both left ventricular (LV) and left atrial (LA) dysfunction and remodelling contribute to adverse outcomes in heart failure with reduced ejection fraction (HFrEF). Danicamtiv is a novel, cardiac myosin activator that enhances cardiomyocyte contraction. METHODS AND RESULTS: , P < 0.01) and increased LA function index (up to 6.1, P < 0.01), when compared with placebo. CONCLUSIONS: Danicamtiv was well tolerated and improved LV systolic function in patients with HFrEF. A marked improvement in LA volume and function was also observed in patients with HFrEF, consistent with pre-clinical findings of direct activation of LA contractility.
Voors et al. (Fri,) studied this question.